These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38966690)

  • 1. Preference for daily (1HP) vs. weekly (3HP) isoniazid-rifapentine among people living with HIV in Uganda.
    Musinguzi A; Aschmann HE; Kadota JL; Nakimuli J; Welishe F; Kakeeto J; Namale C; Akello L; Nakitende A; Berger C; Katamba A; Tumuhamye J; Kiwanuka N; Dowdy DW; Cattamanchi A; Semitala FC
    IJTLD Open; 2024 Feb; 1(2):83-89. PubMed ID: 38966690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of one month of daily isoniazid and rifapentine versus three months of weekly isoniazid and rifapentine for prevention of tuberculosis among people receiving antiretroviral therapy in Uganda.
    Ferguson O; Jo Y; Pennington J; Johnson K; Chaisson RE; Churchyard G; Dowdy D
    J Int AIDS Soc; 2020 Oct; 23(10):e25623. PubMed ID: 33073520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment Responses to Integrase Strand-transfer Inhibitor-containing Antiretroviral Regimens in Combination With Short-course Rifapentine-based Regimens for Latent Tuberculosis Infection Among People With HIV.
    Lin KY; Sun HY; Yang CJ; Lu PL; Lee YT; Lee NY; Liou BH; Tang HJ; Lee MH; Wang NC; Chen TC; Hii IM; Huang SH; Lin CY; Tsai CS; Cheng CY; Hung CC;
    Clin Infect Dis; 2024 May; 78(5):1295-1303. PubMed ID: 38051646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One-month daily and three-month weekly rifapentine plus isoniazid are comparable in completion rate and safety for latent tuberculosis infection in non-HIV Population: a randomized controlled trial.
    Huang HL; Lee MR; Lee CH; Cheng MH; Lu PL; Sheu CC; Wang JY; Chong IW; Yang JM
    Clin Microbiol Infect; 2024 Jul; ():. PubMed ID: 38996972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of 3 optimized delivery strategies for completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV in Uganda: A single-center randomized trial.
    Semitala FC; Kadota JL; Musinguzi A; Welishe F; Nakitende A; Akello L; Kunihira Tinka L; Nakimuli J; Ritar Kasidi J; Bishop O; Nakasendwa S; Baik Y; Patel D; Sammann A; Nahid P; Belknap R; Kamya MR; Handley MA; Phillips PP; Katahoire A; Berger CA; Kiwanuka N; Katamba A; Dowdy DW; Cattamanchi A
    PLoS Med; 2024 Feb; 21(2):e1004356. PubMed ID: 38377166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acceptance and completion of rifapentine-based TB preventive therapy (3HP) among people living with HIV (PLHIV) in Kampala, Uganda-patient and health worker perspectives.
    Semitala FC; Musinguzi A; Ssemata J; Welishe F; Nabunje J; Kadota JL; Berger CA; Katamba A; Kiwanuka N; Kamya MR; Dowdy D; Cattamanchi A; Katahoire AR
    Implement Sci Commun; 2021 Jun; 2(1):71. PubMed ID: 34193311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protocol for the 3HP Options Trial: a hybrid type 3 implementation-effectiveness randomized trial of delivery strategies for short-course tuberculosis preventive therapy among people living with HIV in Uganda.
    Kadota JL; Musinguzi A; Nabunje J; Welishe F; Ssemata JL; Bishop O; Berger CA; Patel D; Sammann A; Katahoire A; Nahid P; Belknap R; Phillips PPJ; Namusobya J; Kamya M; Handley MA; Kiwanuka N; Katamba A; Dowdy D; Semitala FC; Cattamanchi A
    Implement Sci; 2020 Aug; 15(1):65. PubMed ID: 32787925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness-implementation randomized trial.
    Semitala FC; Kadota JL; Musinguzi A; Nabunje J; Welishe F; Nakitende A; Akello L; Bishop O; Patel D; Sammann A; Nahid P; Belknap R; Kamya MR; Handley MA; Phillips PPJ; Katahoire A; Berger CA; Kiwanuka N; Katamba A; Dowdy DW; Cattamanchi A
    PLoS Med; 2021 Dec; 18(12):e1003875. PubMed ID: 34914696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Efficacy of Rifapentine Alone and in Combination with Isoniazid for Latent Tuberculosis Infection: a Translational Pharmacokinetic-Pharmacodynamic Modeling Study.
    Radtke KK; Ernest JP; Zhang N; Ammerman NC; Nuermberger E; Belknap R; Boyd R; Sterling TR; Savic RM
    Antimicrob Agents Chemother; 2021 Nov; 65(12):e0170521. PubMed ID: 34606336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-course daily isoniazid and rifapentine for latent tuberculosis infection in people living with HIV who received coformulated bictegravir/emtricitabine/tenofovir alafenamide.
    Liou BH; Cheng CN; Lin YT; Lin YJ; Chuang YC; Lin KY; Liu WC; Lin SW; Kuo CH; Sun HY; Hung CC
    J Int AIDS Soc; 2021 Nov; 24(11):e25844. PubMed ID: 34822220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse events reported during weekly isoniazid-rifapentine (3HP) tuberculosis preventive treatment among people living with HIV in Uganda.
    Kadota JL; Musinguzi A; Aschmann HE; Akello L; Welishe F; Nakimuli J; Berger CA; Kiwanuka N; Phillips PP; Katamba A; Dowdy DW; Cattamanchi A; Semitala FC
    medRxiv; 2024 Aug; ():. PubMed ID: 39148841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of Preventive Therapy for Tuberculosis With Isoniazid and Rifapentine Versus Isoniazid Alone in High-Burden Settings.
    Johnson KT; Churchyard GJ; Sohn H; Dowdy DW
    Clin Infect Dis; 2018 Sep; 67(7):1072-1078. PubMed ID: 29617965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating the effect of short-course rifapentine-based regimens with or without enhanced behaviour-targeted treatment support on adherence and completion of treatment for latent tuberculosis infection among adults in the UK (RID-TB: Treat): protocol for an open-label, multicentre, randomised controlled trial.
    Rangaka MX; Hamada Y; Duong T; Bern H; Calvert J; Francis M; Clarke AL; Ghanouni A; Layton C; Hack V; Owen-Powell E; Surey J; Sanders K; Booth HL; Crook A; Griffiths C; Horne R; Kunst H; Lipman M; Mandelbaum M; White PJ; Zenner D; Abubakar I
    BMJ Open; 2022 Sep; 12(9):e057717. PubMed ID: 36691120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrating 3HP-based tuberculosis preventive treatment into Zimbabwe's Fast Track HIV treatment model: experiences from a pilot study.
    Mapingure MP; Zech JM; Hirsch-Moverman Y; Msukwa M; Howard AA; Makoni T; Gwanzura C; Apollo T; Sandy C; Musuka GN; Rabkin M
    J Int AIDS Soc; 2023 Jun; 26(6):e26105. PubMed ID: 37339341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Twice-Daily Dolutegravir Based Antiretroviral Therapy with One Month of Daily Rifapentine and Isoniazid (1HP) for TB Prevention.
    Podany AT; Cramer Y; Imperial M; Rosenkranz SL; Avihingsanon A; Arduino R; Samaneka W; Gelmanova I; Savic R; Swindells S; Dawson R; Luetkemeyer AF
    Clin Infect Dis; 2024 Apr; ():. PubMed ID: 38568956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Viral suppression among adults with HIV receiving routine dolutegravir-based antiretroviral therapy and 3 months weekly isoniazid-rifapentine.
    Chaisson LH; Semitala FC; Nangobi F; Steinmetz S; Marquez C; Armstrong DT; Opira B; Kamya MR; Phillips PPJ; Dowdy DW; Yoon C
    AIDS; 2023 Jun; 37(7):1097-1101. PubMed ID: 36779500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and feasibility of 1 month of daily rifapentine plus isoniazid to prevent tuberculosis in children and adolescents: a prospective cohort study.
    Malik AA; Farooq S; Jaswal M; Khan H; Nasir K; Fareed U; Shahbaz S; Amanullah F; Safdar N; Khan AJ; Keshavjee S; Becerra MC; Hussain H
    Lancet Child Adolesc Health; 2021 May; 5(5):350-356. PubMed ID: 33770510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding patient-level costs of weekly isoniazid-rifapentine (3HP) among people living with HIV in Uganda.
    Sung J; Musinguzi A; Kadota JL; Baik Y; Nabunje J; Welishe F; Bishop O; Berger CA; Katahoire A; Nakitende A; Nakimuli J; Akello L; Kasidi JR; Kunihira Tinka L; Kamya MR; Sohn H; Kiwanuka N; Katamba A; Cattamanchi A; Dowdy DW; Semitala FC
    Int J Tuberc Lung Dis; 2023 Jun; 27(6):458-464. PubMed ID: 37231600
    [No Abstract]   [Full Text] [Related]  

  • 19. Cost-effectiveness of 3 months of weekly rifapentine and isoniazid compared with other standard treatment regimens for latent tuberculosis infection: a decision analysis study.
    Doan TN; Fox GJ; Meehan MT; Scott N; Ragonnet R; Viney K; Trauer JM; McBryde ES
    J Antimicrob Chemother; 2019 Jan; 74(1):218-227. PubMed ID: 30295760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient choice improves self-efficacy and intention to complete tuberculosis preventive therapy in a routine HIV program setting in Uganda.
    Lim RK; Semitala FC; Atuhumuza E; Sabiti L; Namakula-Katende J; Muyindike WR; Kamya MR; Dowdy D; Cattamanchi A
    PLoS One; 2021; 16(2):e0246113. PubMed ID: 33539400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.